BRIEF-Mmenta Pharmaceuticals to regain global development and commercialization rights to M923

* Momenta Pharmaceuticals to regain global development and commercialization rights to M923, a proposed biosimilar of HUMIRA (adalimumab), through termination of collaboration agreement with Baxalta, now part of Shire